# Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Source: https://onco.cc/trials/nct02338050/  
OnCo record `nct02338050` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Moxetumomab pasudotox in Acute lymphoblastic leukaemia, run by Center for International Blood and Marrow Transplant Research, recorded as terminated on the registry.

## Summary

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation is a phase 2 interventional study registered as NCT02338050 by Center for International Blood and Marrow Transplant Research, with 1 participants recorded, started 2015-05 and due to reach its primary completion in 2020-05. Interventions recorded: Moxetumomab Pasudotox. Conditions recorded: Acute Lymphoblastic Leukemia (ALL).

Linked to the drug Moxetumomab pasudotox because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02338050
- Phase: 2
- Setting: A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
- Sponsor: Center for International Blood and Marrow Transplant Research
- Enrolled: 1

## Sources

- ClinicalTrials.gov NCT02338050: https://clinicaltrials.gov/study/NCT02338050

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [Moxetumomab pasudotox](https://onco.cc/drugs/moxetumomab-pasudotox/)

---
JSON: https://onco.cc/api/v1/entities/nct02338050.json